Press releases

Press release Nanoform Finland Plc June 15, 2023 08:10 a.m.…

Press release Nanoform Finland Plc May 9, 2023 15.00 Finnish…

Press release Nanoform Finland Plc February 4, 2022 08:10 a.m.…

Press release Nanoform Finland Plc November 12, 2021 11:00 a.m.…

Press release Nanoform Finland Plc May 25, 2021 04:00 p.m.…

Press release Nanoform Finland Plc April 21st, 2021 08:10 a.m.…

Press release Nanoform Finland Plc March 31, 2021 08:10 a.m.…

Press release Nanoform Finland Plc March 22, 2021 08:10 a.m.…

Press release Nanoform Finland Plc February 9th, 2021 08:10 a.m.…

Helsinki, Finland – Finnish Foundation for Share Promotion (Pörssisäätiö/Börsstiftelsen) and…

Helsinki, Finland – Nasdaq announced today the results of the…

PRESS RELEASE Nanoform Finland Plc December 2nd, 2020 4 p.m.…

Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Press Release June 15, 2020 at 8:00 a.m. Finnish time…

Nanoform has appointed Miguel Calado as Chairman of the Board.

Nanoform and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform’s award-winning CESS^® technology to new chemical entities.

Nanoform has established Nanoform USA Inc., a wholly owned subsidiary in the US.

Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.

Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.

Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.

Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.

Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.

Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

Nanoform has unveiled a new brand identity and website. The evolution of Nanoform’s brand reflects how the company is using innovation to transform the pharmaceutical industry and support its global partners as they develop life-changing medicines.

Nanoform accelerates growth with Director of Project Management appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, will appoint Miguel Cansado as its Director of Project Management.

Nanoform awarded with a Seal of Excellence from the European Commission Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project.

Nanoform strengthens GMP capabilities with Head of Manufacturing appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr David Rowe as its Head of Manufacturing.

Nanoform strengthens board with appointment of Vice Chairman Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Miguel Calado as Vice Chairman of the Board.

Nanoform, an innovative drug enabling nanotechnology company, has announced significant progress in the construction of its new 600m2 GMP manufacturing plant, located at Cultivator II in Viikki Life Science Park, Finland.

Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Prof Jukka Corander as Head of AI.

Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Niklas Sandler as Chief Technology Officer.

Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Gonçalo Rebelo de Andrade as Chief of Business Operations.

Nanoform, an innovative drug enabling nanotechnology company, has announced the construction of a GMP manufacturing plant to provide API ‘solution to particle’ nanonization for clinical trials.

Nanoform, a Helsinki, Finland-based drug particle engineering and nanotechnology company, is set to globalize its novel nanonization technology with the appointment of Christian Jones as Chief Commercial Officer.

Nanoform, an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, is continuing its strategic growth through a significant €7 million investment, with Vator Securities acting as the sole bookrunner.